This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2008 Jan;4(1):18-9.

doi: 10.1038/ncpneph0642. Epub 2007 Oct 23.

Utility of oral valganciclovir for the treatment of cytomegalovirus disease after renal transplantation

David A Pegues¹

Affiliations

Affiliation

¹ David Geffen School of Medicine, UCLA Division of Infectious Diseases, 37-121 CHS 10833 Le Conte Avenue, Los Angeles, CA 90095-1688, USA. dpegues@mednet.ucla.edu

PMID: 17955041
DOI: 10.1038/ncpneph0642

Comment

Utility of oral valganciclovir for the treatment of cytomegalovirus disease after renal transplantation

David A Pegues. Nat Clin Pract Nephrol. 2008 Jan.

. 2008 Jan;4(1):18-9.

doi: 10.1038/ncpneph0642. Epub 2007 Oct 23.

Author

David A Pegues¹

Affiliation

¹ David Geffen School of Medicine, UCLA Division of Infectious Diseases, 37-121 CHS 10833 Le Conte Avenue, Los Angeles, CA 90095-1688, USA. dpegues@mednet.ucla.edu

PMID: 17955041
DOI: 10.1038/ncpneph0642

No abstract available

PubMed Disclaimer

Comment on

Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients.
Asberg A, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz MD, Sgarabotto D, Tuncer M, Noronha IL, Hartmann A; VICTOR Study Group. Asberg A, et al. Am J Transplant. 2007 Sep;7(9):2106-13. doi: 10.1111/j.1600-6143.2007.01910.x. Epub 2007 Jul 19. Am J Transplant. 2007. PMID: 17640310 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.